Literature DB >> 25740703

The significance and management of thrombocytopenia in antiphospholipid syndrome.

Bahar Artim-Esen1, Reyhan Diz-Küçükkaya, Murat İnanç.   

Abstract

The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL with a frequency ranging from 20 to 50 %. Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis. However, when anticoagulation is considered, it may constitute a clinical problem with increased bleeding risk. Furthermore, thrombocytopenia represents a risk factor for thrombosis in aPL-positive patients. Therefore, it is important to understand the pathogenesis and the clinical associations of thrombocytopenia to build the right medical approach in aPL-positive patients. In this paper, we review the literature on aPL/APS-associated thrombocytopenia and briefly discuss the other conditions that can result in thrombocytopenia as they have commonalities with APS and their recognition is important to establish the most appropriate treatment strategy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740703     DOI: 10.1007/s11926-014-0494-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  97 in total

Review 1.  Is there a microangiopathic antiphospholipid syndrome?

Authors:  Ronald A Asherson; Sylvia S Pierangeli; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

2.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

3.  Characteristics of the clinical findings in patients with idiopathic thrombocytopenic purpura who are positive for anti-phospholipid antibodies.

Authors:  M Funauchi; K Hamada; H Enomoto; S Ikoma; M Ohno; K Kinoshita; A Horiuchi
Journal:  Intern Med       Date:  1997-12       Impact factor: 1.271

Review 4.  Functions of CD40 and its ligand, gp39 (CD40L).

Authors:  J D Laman; E Claassen; R J Noelle
Journal:  Crit Rev Immunol       Date:  1996       Impact factor: 2.214

Review 5.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

6.  Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies.

Authors:  M Galli; M Daldossi; T Barbui
Journal:  Thromb Haemost       Date:  1994-05       Impact factor: 5.249

Review 7.  Heparin-induced thrombocytopenia.

Authors:  A Greinacher
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

8.  Non-malignant bone marrow necrosis: a report of two cases.

Authors:  J Moore; D D Ma; A Concannon
Journal:  Pathology       Date:  1998-08       Impact factor: 5.306

9.  Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.

Authors:  Valerie Proulle; Richard A Furie; Glenn Merrill-Skoloff; Barbara C Furie; Bruce Furie
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

10.  Bone marrow necrosis related to paracoccidioidomycosis: the first eight cases identified at autopsy.

Authors:  Lucilene S R Resende; Rinaldo P Mendes; Maura M Bacchi; Sílvio A Marques; Benedito Barraviera; Lenice R Souza; Domingos A Meira; Lígia Niéro-Melo
Journal:  Histopathology       Date:  2009-03       Impact factor: 5.087

View more
  13 in total

1.  Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome.

Authors:  Ayten Yazıcı
Journal:  Eur J Rheumatol       Date:  2020-10

2.  Antiphospholipid Syndrome: Multiple Manifestations in a Single Patient-A High Suspicion Is Still Needed.

Authors:  Uroosa Ibrahim; Shiksha Kedia; Gwenalyn Garcia; Jean Paul Atallah
Journal:  Case Rep Med       Date:  2017-05-23

Review 3.  Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Authors:  Andrew P Vreede; Paula L Bockenstedt; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

Review 4.  Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management.

Authors:  Pasquale Pignatelli; Evaristo Ettorre; Danilo Menichelli; Arianna Pani; Francesco Violi; Daniele Pastori
Journal:  Haematologica       Date:  2020-01-30       Impact factor: 9.941

5.  Antiphospholipid Syndrome-Related Pulmonary Embolism: Clinical Characteristics and Early Recognition.

Authors:  Maojing Shi; Weibo Gao; Yuebo Jin; Jihong Zhu; Yuansheng Liu; Tianbing Wang; Chun Li
Journal:  Front Cardiovasc Med       Date:  2022-07-11

6.  A novel aGAPSS-based nomogram for the prediction of ischemic stroke in patients with antiphospholipid syndrome.

Authors:  Xiaodong Song; Yangyi Fan; Yuan Jia; Gongming Li; Meige Liu; Yicheng Xu; Jun Zhang; Chun Li
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

7.  Risk of Systemic Lupus Erythematosus in Patients With Anti-phospholipid Syndrome: A Population-Based Study.

Authors:  Hsin-Hua Chen; Ching-Heng Lin; Wen-Cheng Chao
Journal:  Front Med (Lausanne)       Date:  2021-05-10

8.  Association of anticardiolipin, antiphosphatidylserine, anti-β2 glycoprotein I, and antiphosphatidylcholine autoantibodies with canine immune thrombocytopenia.

Authors:  Yu-Chen Chen; Lang-Ming Chi; Kuan-Chih Chow; Shiow-Her Chiou; Yi-Hsin Fan; Shu-Peng Ho; Yu-Chen Hsu; Yu-Chyi Hwang; Meng-Xing Wu; Wei-Ming Lee; Shiun-Long Lin; Chau-Loong Tsang; Frank Chiahung Mao
Journal:  BMC Vet Res       Date:  2016-06-13       Impact factor: 2.741

9.  Chronic Thromboembolic Pulmonary Hypertension and Antiphospholipid Syndrome with Immune Thrombocytopenia: A Case Report.

Authors:  Andris Skride; Matiss Sablinskis; Kristaps Sablinskis; Sandra Lejniece; Aivars Lejnieks; Walter Klepetko; Irene M Lang
Journal:  Am J Case Rep       Date:  2018-10-19

Review 10.  Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia.

Authors:  Siyu Sun; Rolf T Urbanus; Hugo Ten Cate; Philip G de Groot; Bas de Laat; Johan W M Heemskerk; Mark Roest
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.